Cardizem (R) (Diltiazem HC1 for injection) Monvial (R)

Hoechst Marion Roussel

Approval Status
Approved September 1997

Treatment for
atrial fibrillation

Cardiovascular / Cardiology

Hoeschst Marion Roussel announced that Cardizem (R) (diltiazem HC1 for injection) Monovial (R) has been cleared for use in the U.S. by the FDA. Cardizem Monovial is an advanced infusion delivery system for Cardizem Injectable, a widely prescribed compound for treatment of certain heartbeat irregularities.

Cardizem Monovial is indicated for maintenance heart rate control in patients with atrial fibrillation or atrial flutter for up to 24 hours. Cardizem Monovial is expected to be available beginning in early 1998.

The most commonly reported adverse events are asymptomatic hypotension (4.3%), symptomatic hypotension (3.2%), injection site reaction (3.9%), flushing (1.7%), and arrhythmia (1.0%).

Cardizem (R) (Diltiazem HC1 for injection) Monvial (R) Drug Information

The Cardizem (R) (Diltiazem HC1 for injection) Monvial (R) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top